Skip to main content
Find more clinical trials

Skills Training for Caregivers of People With Primary Progressive Aphasia

Start: July 30, 2020
End: July 30, 2022
Enrollment: 68

What Is This Study About?

The Tele-Savvy program is designed to lower caregiver stress and increase knowledge about providing care. This study aims to adapt and test the Tele-Savvy online caregiver training program to address the unique challenges of caregiving for a person with primary progressive aphasia (PPA). Participants will join weekly, two-hour online classes over seven weeks. Researchers will engage the participants to adapt the existing Tele-Savvy program to meet their needs and then pilot test the adapted PPA Tele-Savvy program. Interviews and questionnaires will measure changes in caregiver stress, quality of life, and changes in care recipients behavioral problems.

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: N/A

Must have:

  • Informal caregivers of a person living with or deceased from PPA
  • Providing, now or in the past, at least two hours per day of unpaid assistance, on average, for a person in the early or middle stages of PPA
  • Access to a computer with a good internet connection
  • Able to use a videoconferencing platform and receive email
  • Able to read, speak, and understand English

Must NOT have:

  • Vision or hearing problems that cannot be adequately corrected for study participation

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 
Study Contact
Darby Morhardt, PhD
Lisa Rawlani

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Illinois
Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University
Chicago, IL 60611
Recruiting
Darby Morhardt, PhD

Who Sponsors This Study?

Lead: Northwestern University

Collaborator Sponsor

  • Emory University

Source: ClinicalTrials.gov ID: NCT04412083